US Patent 9475874 Nucleic acids encoding human antibodies to sialyl-lewis
Patent 9475874 was granted and assigned to Mabvax Therapeutics on October, 2016 by the United States Patent and Trademark Office.
All edits
The present invention provides compositions for the production of an antibody or functional fragment thereof directed against Sialyl-Lewisa (sLea). The compositions of the invention include polynucleotides encoding a heavy chain and/or a light chain variable domain that binds to sLea. The invention also provides an isolated antibody or functional fragment thereof and methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a diagnostic agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.
US Patent 09475874 Nucleic acids encoding human antibodies to sialyl-lewis US Patent 9475874 Nucleic acids encoding human antibodies to sialyl-lewis
US Patent 09475874 Nucleic acids encoding human antibodies to sialyl-lewis
Find more entities like US Patent 9475874 Nucleic acids encoding human antibodies to sialyl-lewis
